In a first-in-human clinical trial, currently active but not recruiting, researchers are pioneering the use of CAR NK cells in the treatment of glioblastoma, with a specific focus on HER2-positive glioblastoma (NCT03383978). This evidence concerns the gene ERBB2 and glioblastoma.